Abstract 248P
Background
Many patients concern the body imbalance after mastectomy and it is often cited as justification for immediate-breast reconstruction (IBR). However, few studies have investigated the impact of mastectomy or IBR on scoliosis, and analyzed only a small number of patients. We investigated whether mastectomy impacts spine alignment compared to IBR with a large cohort.
Methods
We retrospectively reviewed the patients who underwent breast cancer surgery between 2004 and 2018 at a single institution. Using the deep learning-based algorithm (DeepNoid Inc.), we collected Cobb's angle from chest posteroanterior x-rays at three time points: pre-operation, postoperative one-year, and five-years. Patients who underwent bilateral surgery, delayed-reconstruction, or LD-flap were excluded.
Results
Totally 6246 patients were included: 3442 (55.1%), 1911 (30.6%), and 893 (14.3%) patients underwent breast-conservation surgery (BCS), mastectomy without IBR, and IBR, respectively. At postoperative five-years, the mastectomy group showed the significantly greater change in Cobb's angle compared to both the BCS (p<0.001) and IBR (p=0.004) groups, while there was no significant difference between the BCS and IBR groups (p=0.347). After adjusting for other clinicopathologic variables, operation methods, adjuvant hormone treatments, and the direction of cancer remained significant factors affecting vertebral alignment. However, there was no relationship between the excised breast weights and Cobb's angle. Propensity score matching also showed that mastectomy group has greater change in angle compared to the other groups (vs. BCS, p=0.041; vs. IBR, p=0.047). Cobb’s angle was more evidence among patients under 50 years old (p=0.016) and who administered hormone treatment (p=0.009). Lastly, significantly more patients experienced lumbar pain after mastectomy (8.4%) than after BCS (6.7%) or IBR (4.1%) during the surveillance (p<0.001).
Conclusions
This is the largest study that showed the significant change in thoracic spine alignment after mastectomy compared to BCS and IBR. The results would provide the evidence on recommending breast reconstruction especially for young patients and educating post-mastectomy postural correction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Seoul National University Hospital.
Disclosure
H. Lee; W. Han: Financial Interests, Personal, Stocks or ownership, Not relevant to this study: DCGen. All other authors have declared no conflicts of interest.
Resources from the same session
1988P - Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study
Presenter: Tanya Jindal
Session: Poster session 13
1989P - Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis
Presenter: Albert Jang
Session: Poster session 13
1990P - MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study
Presenter: Chuanliang Cui
Session: Poster session 13
1992P - Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC)
Presenter: Hedyeh Ebrahimi
Session: Poster session 13
1993P - A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option
Presenter: Anishka D'Souza
Session: Poster session 13
1994P - Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)
Presenter: Bradley McGregor
Session: Poster session 13
1995P - Insights into second-line (2L) systemic treatment (tx) receipt in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 13
1996P - Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan
Presenter: Eiji Kikuchi
Session: Poster session 13
1997P - Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC)
Presenter: Sarmad Sadeghi
Session: Poster session 13